EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis



Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis



Rheumatology International 29(4): 431-436



The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus for treating rheumatoid arthritis (RA) patients in clinical practice. Fifty-five active RA patients who had been resistant or intolerant to other disease-modifying antirheumatic drugs were enrolled in this open-label trial. Patients were administered tacrolimus at a dosage of 1, 2 or 3 mg once daily, and followed up for 24 weeks. They were divided into three groups according to their dosage. Efficacy and safety were evaluated utilizing clinical and laboratory findings. Eighty percent of the patients had moderate or high disease activity; 55% were elderly and 53% had complications; 65% of the patients were started on tacrolimus as a monotherapy. Moderate or good response rates were achieved as follows: 38.2% (4 weeks); 41.8% (12 weeks); and 45.6% (24 weeks). Adverse events were observed in seven cases (12.7%). Only one case required hospitalization due to severe hyperglycemia caused by a high tacrolimus concentration (24.2 ng/ml); we suspected a drug interaction in this subject. Mean concentrations were dose-dependent in the 1, 2, and 3 mg/day groups (2.96, 4.29, and 8.32 ng/ml, respectively). Four cases of high concentration (over 10 ng/ml), without any signs or symptoms, were observed in the 3 mg/day group; in these cases, doses were decreased and no severe adverse events occurred. Tacrolimus was found to be both effective and safe in treating active RA patients with complicated backgrounds in clinical practice. Blood concentration measurements and dose adjustments should be performed to prevent severe adverse events in a 3 mg/day group.

(PDF same-day service: $19.90)

Accession: 055793443

Download citation: RISBibTeXText

PMID: 19127365

DOI: 10.1007/s00296-008-0833-z



Related references

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatology International 31(6): 757-763, 2011

Prospective study for the efficacy and safety of tacrolimus in a consecutive 100 cases with rheumatoid arthritis. 2007

Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clinical Rheumatology 31(2): 251-257, 2012

Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint, Bone, Spine 79(4): 365-369, 2012

A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). Transplantation Proceedings 47(3): 617-621, 2015

Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. Journal of Rheumatology 31(2): 243-251, 2004

Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis. Modern Rheumatology 18(3): 296-300, 2008

Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. International Journal of Rheumatic Diseases 19(7): 651-657, 2015

Efficacy & safety evaluation of Ayurvedic treatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study. Indian Journal of Medical Research 141(1): 100-106, 2016

Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study. Clinical Drug Investigation 24(2): 103-112, 2007

Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry. Modern Rheumatology 25(6): 825-830, 2016

The efficacy and safety of tacrolimus in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 3(6): 283-291, 2012

Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Modern Rheumatology 20(5): 478-485, 2011

The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial. Zhonghua Nei Ke Za Zhi 52(4): 323-329, 2015

Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis assessment of tolerance and efficacy in a single center 24 week double blind parallel study. Scandinavian Journal of Rheumatology 13(4): 342-350, 1984